Lexicon Pharmaceuticals | LXRX - Actif À Court Terme





Actif À Court Terme Changement Date
Abbott USD 25.51B 488M 2026-03
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Akebia Therapeutics USD 243.48M 9.47M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
AstraZeneca USD 29.61B 890M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Coherus Biosciences USD 206.71M 254.25M 2025-12
Eli Lilly USD 54.84B 794M 2026-03
Esperion Therapeutics USD 459.46M 3.11M 2026-03
Halozyme Therapeutics USD 1B 177.83M 2026-03
Illumina USD 2.74B 551M 2026-03
Insmed USD 1.61B 181.04M 2026-03
Ironwood Pharmaceuticals USD 332.29M 58.11M 2026-03
J&J USD 59.17B 3.55B 2026-03
Lexicon Pharmaceuticals USD 186.03M 84.14M 2026-03
MacroGenics USD 182.52M 37.42M 2026-03
MannKind USD 251.16M 40.42M 2026-03
Merck USD 35.02B 8.5B 2026-03
Moderna USD 5.77B 774M 2026-03
Novartis USD 26.61B 3.85B 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Puma Biotechnology USD 143.58M 7M 2025-09
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Thermo Fisher Scientific USD 22.32B 6.39B 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
United Therapeutics USD 2.87B 830.5M 2026-03
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12